-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Irinotecan in combination with cetuximab approved for irinotecan-refractory metastatic diseaseColorectal cancer (mCRC)
Irinotecan in combination with cetuximab approved for irinotecan-refractory metastatic diseaseColorectal cancer (mCRC)
This is a multicenter, randomized, double-blind, placebo-controlled phase II trial of irinotecan-refractory metastatic colorectal cancer (mCRC) previously untreated with anti-EGFR therapy
This is a multicenter, randomized, double-blind, placebo-controlled phase II trial of irinotecan-refractory metastatic colorectal cancer (mCRC) previously untreated with anti-EGFR therapy
Due to a change in funding, the study ended prematurely after 36 patients completed out of a planned enrollment of 120 patients
Due to a change in funding, the study ended prematurely after 36 patients completed out of a planned enrollment of 120 patients
The median PFS for CBI and CI was 9.
The median PFS for CBI and CI was 9.
The ORR was 36.
The ORR was 36.
There was no significant difference in the incidence of grade 1 and 2 AEs between the two groups
In conclusion, the study shows that CBI combined therapy cannot improve the PFS of patients, but improves the OS of patients, which is worthy of further exploration in the future
Original source:
Marla Lipsyc-Sharf1 , Fang-Shu Ou , Matthew B.
Marla Lipsyc-Sharf1 , Fang-Shu Ou , Matthew B.
Yurgelun, et al.
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
The Oncologist, 2022, XX, 1 –7 .
https://doi.
org/10.
1093/oncolo/oyab025.
Leave a comment here